TY  - JOUR
AU  - Piechotta, Paula L
AU  - Bonekamp, David
AU  - Sill, Martin
AU  - Wick, Antje
AU  - Wick, Wolfgang
AU  - Bendszus, Martin
AU  - Kickingereder, Philipp
TI  - Increased Delay Between Gadolinium Chelate Administration and T1-Weighted Magnetic Resonance Imaging Acquisition Increases Contrast-Enhancing Tumor Volumes and T1 Intensities in Brain Tumor Patients.
JO  - Investigative radiology
VL  - 53
IS  - 4
SN  - 0020-9996
CY  - Philadelphia, Pa.
PB  - Lippincott Williams & Wilkins
M1  - DKFZ-2018-00381
SP  - 223 - 228
PY  - 2018
AB  - The aim of this study was to evaluate the impact of delayed T1-weighted (T1-w) MRI acquisition after gadolinium chelate administration on brain tumor volumes and T1-w intensities.Fifty-five patients with histologically confirmed, contrast-enhancing intra-axial brain tumors were analyzed in this prospective test-retest study. Patients underwent 2 consecutive 3 T MRI scans (separated by a 1-minute break) during routine follow-up with contrast-enhanced T1 (ceT1-w), T2, and FLAIR acquisition. Macrocyclic gadolinium chelate-based contrast agent was only administered before the first ceT1-w acquisition; median latency to ceT1-w acquisition was 6.72 minutes (IQR, 6.53-6.92) in the first and 16.27 minutes (IQR, 15.49-17.26) in the second scan. Changes in tumor volumes and relative ceT1-w intensities between the 2 acquisitions were quantitatively assessed following semiautomated tumor segmentation (separately for contrast-enhancement [CE], necrosis [NEC], and nonenhancing [NE] tumor).Semiautomatically segmented CE tumor volumes were significantly larger in the second acquisition (median +32
LB  - PUB:(DE-HGF)16
C6  - pmid:29200014
DO  - DOI:10.1097/RLI.0000000000000432
UR  - https://inrepo02.dkfz.de/record/132727
ER  -